Synagis®: Resources and Support | Tools to learn more about RSV

Having the facts about RSV and RSV protection right at your fingertips is important. But sometimes it's just good to know you're not the only one going through this.

These resources can help you tap into an extended community of RSV experts, parents and advocates. So whether you're looking for helpful links, a quick answer or ways to reach out to others, this is the place to learn and grow.

This is your chance to speak up about RSV. Learn more about the Thrive Network, where your experience and insights can help others understand the importance of RSV protection. Get started by sharing your story.

Know someone who should really learn more about RSV and Synagis? Want to introduce a friend to the Thrive Network? Use these e-cards to help spread the word about RSV protection and Synagis.com

Find answers to some of the most common questions about RSV and Synagis.

Get more information from outside resources such as the CDC.

Important Safety Information

Synagis® (palivizumab) is indicated for the prevention of serious lung infections caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Synagis is given as a shot, usually in the thigh muscle, each month during the RSV season. The first dose of Synagis should be given before RSV season begins. Children who develop an RSV infection while receiving Synagis should continue the monthly dosing schedule throughout the season. Synagis has been used in more than one million children in the U.S. since its introduction in 1998.

Very rare cases (<1 per 100,000 patients) of severe allergic reactions such as anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. These rare reactions may occur when any dose of Synagis is given, not just the first one. Also, rare but serious side effects can occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Other side effects with Synagis may include upper respiratory tract infection, ear infection, fever, and runny nose. In children born with heart problems, Synagis was associated with reports of low blood oxygen levels and abnormal heart rhythms. Synagis should not be used in patients with a history of a severe prior reaction to Synagis or its components. Side effects, such as, skin reactions around the area where the shot was given (like redness, swelling, warmth, or discomfort) can also occur.